Vision Response to Dopamine Replacement
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01663935 |
Recruitment Status
:
Recruiting
First Posted
: August 14, 2012
Last Update Posted
: May 4, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Albinism Oculocutaneous Albinism | Drug: Levodopa/carbidopa | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Interventional Study of Levodopa Replacement on Retinal Function in Oculocutaneous Albinism |
Study Start Date : | August 2012 |
Estimated Primary Completion Date : | September 2017 |
Estimated Study Completion Date : | October 2017 |

Arm | Intervention/treatment |
---|---|
Levodopa/carbidopa 4mg/kg/day
Treatment drug taken orally three times daily
|
Drug: Levodopa/carbidopa
This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.
Other Names:
|
- Visual Acuity Improvement [ Time Frame: 3 months ]Change in visual acuity as measured in logMAR by Snellen or Sweep visual evoked potential (SVEP)
- Retinal Function [ Time Frame: 3 months ]Electroretinography -- electro physiologic testing of retinal function
- Color and Contrast sensitivity [ Time Frame: 3 months ]Ancillary testing of visual/retinal function

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 3 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- clinical diagnosis of oculocutaneous albinism
- age over 3 and weight over 25 lbs.
Exclusion Criteria:
- ocular only albinism
- ocular pathology other than albinism
- neurologic disease, history of myocardial infarction, history of clinical depression, pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01663935
Contact: Michael C Struck, MD | 608-263-9859 | mcstruck@wisc.edu | |
Contact: Angie Wealti | 608-265-7557 | Angie Wealti <wealti@ophth.wisc.edu> |
United States, Wisconsin | |
University of Wisconsin | Recruiting |
Madison, Wisconsin, United States, 53705 | |
Contact: Angie Wealti 608-265-7557 Angie Wealti <wealti@ophth.wisc.edu> | |
Principal Investigator: Michael C Struck, MD |
Principal Investigator: | Michael C Struck, MD | University of Wisconsin, Madison |
Responsible Party: | University of Wisconsin, Madison |
ClinicalTrials.gov Identifier: | NCT01663935 History of Changes |
Other Study ID Numbers: |
2016-1576 2012-0023 ( Other Identifier: Study team ) |
First Posted: | August 14, 2012 Key Record Dates |
Last Update Posted: | May 4, 2017 |
Last Verified: | May 2017 |
Keywords provided by University of Wisconsin, Madison:
levodopa Albinism dopamine |
oculocutaneous albinism vision retina function |
Additional relevant MeSH terms:
Hypopigmentation Albinism Albinism, Oculocutaneous Eye Diseases, Hereditary Eye Diseases Genetic Diseases, Inborn Amino Acid Metabolism, Inborn Errors Metabolism, Inborn Errors Skin Diseases, Genetic Pigmentation Disorders Skin Diseases Metabolic Diseases Levodopa Carbidopa |
Dopamine Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Cardiotonic Agents Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Protective Agents Aromatic Amino Acid Decarboxylase Inhibitors Enzyme Inhibitors |